Bipolar Disorder

Here are a few reminders to help avoid both toxicity and loss of effectiveness.

The FDA has approved dexmedetomidine sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Today is World Bipolar Day! Celebrate with the freshest clinical pearls on bipolar disorder that Psychiatric Times has to offer.

Predicting mania versus psychosis: Researchers performed a retrospective study of prodromal symptoms, risk factors, and vulnerability markers in first-episode mania and psychosis.

Researchers performed an RCT of pramipexole for patients with bipolar disorder and cognitive impairment.

Although research is limited, the results are promising.

Two forms of telehealth can improve quality of life and care for patients with PTSD and bipolar disorder who live in more rural communities.

Treatment decisions lie on a continuum—befitting a dimensional approach to diagnosis.

Alkermes announced positive results from their phase 3b ENLIGHTEN-Early study.

Exploring cognitive biases toward the DSM and their avoidable effects on treatment decisions.

Sleep, depression, and bipolar disorder: what's the connection?

Sleep disturbances in borderline personality disorder are relatively unrecognized.

Have you had difficulty with differential diagnosis when patients have manic symptoms and psychosis? One doctor discusses the related DSM-5 criteria changes and some of their implications for psychopharmacology.

Patients weigh in on their experiences living with and receiving treatment for the disorder.

Caplyta is now FDA-approved for depressive episodes from bipolar I and II.

This infrequent, but important, toxic effect of lithium deserves increased awareness.

Need a recap of the custom Around the Practice video program on bipolar disorder? We've got you covered.

Don't fall into the trap of these 3 myths about mania in bipolar disorder...

Major depressive episode and bipolar disorders: same DSM-5 diagnostic criteria, but very different disorders.

Michael E. Thase, MD; Theresa Cerulli, MD; Gustavo Alva, MD, DFAPA; and Tina Matthews-Hayes, DNP, FNP, PMHNP, provide insight on the role of telemedicine in improving outcomes for patients with bipolar disorder.

A panel of experts in psychiatry consider the use of a novel second-generation antipsychotic for the management of treatment resistant depression.

Michael E. Thase, MD, presents the case of a 47-year-old man with treatment resistant bipolar depression.

Psychiatric experts consider mood stabilizers when treating bipolar disorder and review the role of antidepressants in disease management.

Theresa Cerulli, MD, and Tina Matthew-Hayes, DNP, FNP, PMHNP, review diagnostic difficulties of the patient’s primary care physician in patient case #1 and share optimal approaches to the diagnosis and treatment for patients with bipolar disorder.

Tina Matthews-Hayes, DNP, FNP, PMHNP, comments on screening tools for bipolar disorder and Gustavo Alva, MD, DFAPA, shares his impressions from patient case #1.

A panel of experts in psychiatry share insights on the challenges and importance of making an accurate diagnosis of bipolar disorder.

Experts in psychiatry review the case of a 27-year-old woman who presents for evaluation of a complex depressive disorder.

Caplyta shows promise as a monotherapy for patients with bipolar I or bipolar II disorder experiencing a major depressive episode

At the Annual Psychiatric Times World CME Conference, an all-star lineup of presenters will share their latest research. Check out this preview of the full agenda.